[HTML][HTML] Bridging biological cfDNA features and machine learning approaches
T Moser, S Kühberger, I Lazzeri, G Vlachos, E Heitzer - Trends in Genetics, 2023 - cell.com
Liquid biopsies (LBs), particularly using circulating tumor DNA (ctDNA), are expected to
revolutionize precision oncology and blood-based cancer screening. Recent technological …
revolutionize precision oncology and blood-based cancer screening. Recent technological …
[HTML][HTML] Liquid biopsies beyond mutation calling: genomic and epigenomic features of cell-free DNA in cancer
AK Angeles, F Janke, S Bauer, P Christopoulos… - Cancers, 2021 - mdpi.com
Simple Summary Liquid biopsies provide a non-invasive means to diagnose and profile
tumors when tissue is not available. Sequence-based analysis of cell-free DNA (cfDNA) is …
tumors when tissue is not available. Sequence-based analysis of cell-free DNA (cfDNA) is …
[HTML][HTML] Toward the early detection of cancer by decoding the epigenetic and environmental fingerprints of cell-free DNA
Y Van Der Pol, F Mouliere - Cancer cell, 2019 - cell.com
Widespread adaptation of liquid biopsy for the early detection of cancer has yet to reach
clinical utility. Circulating tumor DNA is commonly detected though the presence of genetic …
clinical utility. Circulating tumor DNA is commonly detected though the presence of genetic …
Next-generation liquid biopsies: embracing data science in oncology
Deeper and broader sequencing of circulating tumor DNA (ctDNA) has identified a wealth of
cancer markers in the circulation, resulting in a paradigm shift towards data science-driven …
cancer markers in the circulation, resulting in a paradigm shift towards data science-driven …
[HTML][HTML] Bioinformatics analysis for circulating cell-free DNA in cancer
Molecular analysis of cell-free DNA (cfDNA) that circulates in plasma and other body fluids
represents a “liquid biopsy” approach for non-invasive cancer screening or monitoring. The …
represents a “liquid biopsy” approach for non-invasive cancer screening or monitoring. The …
Liquid biopsy of methylation biomarkers in cell-free DNA
H Luo, W Wei, Z Ye, J Zheng, R Xu - Trends in molecular medicine, 2021 - cell.com
Liquid biopsies, in particular, analysis of cell-free DNA (cfDNA), have emerged as a
promising noninvasive diagnostic approach in oncology. Abnormal distribution of DNA …
promising noninvasive diagnostic approach in oncology. Abnormal distribution of DNA …
[HTML][HTML] Towards precision medicine: advances in 5-hydroxymethylcytosine cancer biomarker discovery in liquid biopsy
Robust and clinically convenient biomarkers for cancer diagnosis, early detection, and
prognosis have great potential to improve patient survival and are the key to precision …
prognosis have great potential to improve patient survival and are the key to precision …
[HTML][HTML] The dawn of the liquid biopsy in the fight against cancer
IG Domínguez-Vigil, AK Moreno-Martínez, JY Wang… - Oncotarget, 2018 - ncbi.nlm.nih.gov
Cancer is a molecular disease associated with alterations in the genome, which, thanks to
the highly improved sensitivity of mutation detection techniques, can be identified in cell-free …
the highly improved sensitivity of mutation detection techniques, can be identified in cell-free …
[HTML][HTML] Refined characterization of circulating tumor DNA through biological feature integration
Circulating tumor DNA (ctDNA) in blood plasma is present at very low concentrations
compared to cell-free DNA (cfDNA) of non-tumor origin. To enhance ctDNA detection, recent …
compared to cell-free DNA (cfDNA) of non-tumor origin. To enhance ctDNA detection, recent …
[HTML][HTML] Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system?
M Yang, ME Forbes, RL Bitting, SS O'Neill, PC Chou… - Annals of …, 2018 - Elsevier
Tissue biopsy is the standard diagnostic procedure for cancer. Biopsy may also provide
material for genotyping, which can assist in the diagnosis and selection of targeted therapies …
material for genotyping, which can assist in the diagnosis and selection of targeted therapies …